NCT07137637 2025-08-22HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid LeukemiaHangzhou Polymed Biopharmaceuticals, Inc.Phase 1 Not yet recruiting60 enrolled
NCT02292225 2023-02-27Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)SecuraBioPhase 1 Terminated3 enrolled